Safety of unoprostone isopropyl as mono- or adjunctive therapy in patients with primary open-angle glaucoma or ocular hypertension

Drug Safety

Volumn 25, Issue 8, 2002, Pages 583-597

  De Arruda Mello, Paulo Augusto ^a   Yannoulis, Natalia C ^b   Haque, Reza M ^c  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b Novartis Ophthalmics AG   (Switzerland)

^c Novartis Ophthalmics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETAXOLOL; BRIMONIDINE; DORZOLAMIDE; TIMOLOL MALEATE; UNOPROSTONE ISOPROPYL ESTER;

ADULT; AGED; ASTHMA; BLEPHARITIS; CLINICAL TRIAL; CONJUNCTIVA DISEASE; CONJUNCTIVITIS; CORNEA INJURY; DRUG INDUCED DISEASE; DRUG SAFETY; DRY EYE; EYE DISEASE; EYELID DISEASE; FEMALE; FOREIGN BODY; HEADACHE; HUMAN; HYPERTENSION; INSOMNIA; INTRAOCULAR HYPERTENSION; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OPEN ANGLE GLAUCOMA; PATIENT SELECTION; PHOTOPHOBIA; PRIORITY JOURNAL; RASH; REVIEW; TACHYCARDIA; TASTE DISORDER; THORAX PAIN; VERTIGO; VISUAL DISORDER; XEROSTOMIA;

EID: 0036334239     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200225080-00004     Document Type: Review

References (47)

1. Effect of topical application of Rescula® on ocular circulation
2. Effect of isopropyl unoprostone (Rescula®) topical administration on ophthalmic blood velocity in patients with normal-tension glaucoma
3. Changes in rabbit capillary blood flow and corneal temperature with topically applied UF-021, bunazosin hydrochloride and propranolol hydrochloride
4. Effect of UF-021 on optic nerve head circulation in rabbits
5. Effect of isopropyl unoprostone on choroidal circulation: Changes in choroidal blood flow and intraocular pressure with topical application
6. Effect of topically applied isopropyl unoprostone on microcirculation in the human ocular fundus evaluated with a laser speckle microcirculation analyser
7. Long-term effect of topically applied isopropyl unoprostone on microcirculation in the choroid-retina
8. Clinical evaluation of UF-021 ophthalmic solution in glaucoma patients refractory to maximum tolerable therapy
9. Phase II double-masked dose-determination study of UF-021 (Rescula®) ophthalmic solution in primary open-angle glaucoma and ocular hypertension
10. Double-masked comparative study of UF-021 and timolol ophthalmic solutions in patients with primary open-angle glaucoma or ocular hypertension
11. The clinical evaluation of UF-021, a new prostaglandin related compound, in low tension glaucoma patients
12. Clinical study of UF-021 (Rescula®) ophthalmic solution in refractory glaucoma
13. Clinical study of UF-021 (Rescula®) ophthalmic solution, a novel metabolite-type prostaglandin for the treatment of glaucoma and ocular hypertension
14. Ocular effects of topical instillation of UF-021 ophthalmic solution in healthy volunteers
15. Ocular effects of continuous topical instillations of UF-021 ophthalmic solution in healthy volunteers [in Japanese]
16. Early phase II clinical study of UF-021 ophthalmic solution in primary open-angle glaucoma or ocular hypertension patients
17. Comparison of the effect of different concentrations of the docosanoid unoprostone isopropyl on intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension
18. Unoprostone as adjunctive therapy to timolol: A double-masked randomized study versus brimonidine and dorzolamide
19. Additive efficacy of unoprostone isopropyl 0.12% (Rescula®) to latanoprost 0.005%
20. A double-masked randomized comparison of the efficacy and safety of unoprostone with timolol and betaxolol in patients with primary open-angle glaucoma (including pseudoexfoliation glaucoma), or ocular hypertension. 6 Month Data
21. Effects of unoprostone isopropyl in ocular blood flow decrease induced by systemic vasoconstrictor administration in cynomolgus monkeys
22. Comparison of the vasoactive effects of the docosanoid unoprostone and selected prostanoids on isolated perfused retinal arterioles
23. Partial antagonism of endothelin 1-induced vasoconstriction in the human choroid by topical unoprostone isopropyl
24. Retinal ganglion cell survival after transient ligation of the ophthalmic vessels and administration of unoprostone isopropyl
25. Neuroprotection by unoprostone, but not by latanprost, against glutamate-stimulated calcium influx and cell death in retinal ganglion cells
26. Protective effects against light damage to the photoreceptor by topical application with isopropyl unoprostone ophthalmic solution
27. Safety of the docosanoid unoprostone isopropyl 0.15% when used adjunctively with brimonidine tartrate 0.2% or dorzolamide HCl 2.0% in patients with primary open-angle glaucoma or ocular hypertension
28. The efficacy and safety of unoprostone isopropyl 0.15%, timolol maleate 0.5%, and betaxolol hydrochloride 0.5% in patients with primary open-angle glaucoma or ocular hypertension: Month 12 data
29. Comparison of the cardiovascular effects of unoprostone 0.15%, timolol 0.5%, and placebo in healthy adults during exercise using a treadmill test
30. Comparison of the IOP-lowering efficacy and safety of the docosanoid unoprostone isopropyl 0.15% versus timolol maleate 0.5% dosed twice daily for 6 months in patients with primary open-angle glaucoma or ocular hypertension
31. Safety of unoprostone isopropyl 0.15% ophthalmic solution in patients with mild-to-moderate asthma
32. Clinical evaluation of UF-021 (Rescula®; isopropyl unoprostone)
33. Changes in ocular surface caused by antiglaucomatous eyedrops: Prospective, randomised study for the comparison of 0.5% timolol vs 0. 12% unoprostone
34. A comparison of the intraocular pressure-lowering effect of 0.5% timolol maleate and the docosanoid derivative of a PGF2 alpha metabolite, 0.12% unoprostone, in subjects with chronic open-angle glaucoma or ocular hypertension
35. The effects of unoprostone isopropyl 0.12% and timolol maleate 0.5% on diurnal intraocular pressure
36. The ocular hypotensive effect of concomitant use of isopropyl unoprostone (Rescula®) and timolol
37. Interaction between a prostaglandin F2 alpha derivative, UF-021, and pilocarpine in ocular hypotensive therapy
38. Physician's desk reference for ophthalmology
39. Iris-color change developed after topical isopropyl unoprostone treatment
40. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning: A comparison with fimolol
41. Comparison of latanoprost and fimolol in patients with ocular hypertension and glaucoma
42. A six-month, randomized double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension
43. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color